Patient demographics and baseline characteristics (intent-to-treat population)
| Characteristic . | Parsaclisib monotherapy (N = 72) . | Parsaclisib + itacitinib (N = 11) . | Parsaclisib + R-ICE (N = 5) . |
|---|---|---|---|
| Age, median (range), y | 66 (30-89) | 67 (24-82) | 64 (52-72) |
| >65 years, n (%) | 37 (51) | 7 (64) | 1 (20) |
| Male sex, n (%) | 41 (57) | 6 (55) | 3 (60) |
| Race, n (%) | |||
| White/Caucasian | 57 (79) | 9 (82) | 4 (80) |
| Black/African American | 8 (11) | 1 (9) | 0 |
| Asian | 0 | 0 | 0 |
| Other* | 7 (10) | 1 (9) | 1 (20) |
| Disease type, n (%) | |||
| CLL | 6 (8) | 1 (9) | 0 |
| DLBCL | 23 (32) | 6 (55) | 5 (100) |
| FL | 14 (19) | 1 (9) | 0 |
| HL | 10 (14)† | 2 (18)‡ | 0 |
| MCL | 9 (13) | 1 (9) | 0 |
| MZL | 9 (13)§ | 0 | 0 |
| WM | 1 (1) | 0 | 0 |
| Duration since initial diagnosis, median (range), y | 4.95 (0.5-22.5) | 3.2 (0.4-13.2) | 0.8 (0.5-6.3) |
| ≥3 prior systemic therapy regimens, n (%) | 39 (54) | 5 (45) | 0 |
| Prior HSCT, n (%) | 21 (29) | 1 (9) | 0 |
| Characteristic . | Parsaclisib monotherapy (N = 72) . | Parsaclisib + itacitinib (N = 11) . | Parsaclisib + R-ICE (N = 5) . |
|---|---|---|---|
| Age, median (range), y | 66 (30-89) | 67 (24-82) | 64 (52-72) |
| >65 years, n (%) | 37 (51) | 7 (64) | 1 (20) |
| Male sex, n (%) | 41 (57) | 6 (55) | 3 (60) |
| Race, n (%) | |||
| White/Caucasian | 57 (79) | 9 (82) | 4 (80) |
| Black/African American | 8 (11) | 1 (9) | 0 |
| Asian | 0 | 0 | 0 |
| Other* | 7 (10) | 1 (9) | 1 (20) |
| Disease type, n (%) | |||
| CLL | 6 (8) | 1 (9) | 0 |
| DLBCL | 23 (32) | 6 (55) | 5 (100) |
| FL | 14 (19) | 1 (9) | 0 |
| HL | 10 (14)† | 2 (18)‡ | 0 |
| MCL | 9 (13) | 1 (9) | 0 |
| MZL | 9 (13)§ | 0 | 0 |
| WM | 1 (1) | 0 | 0 |
| Duration since initial diagnosis, median (range), y | 4.95 (0.5-22.5) | 3.2 (0.4-13.2) | 0.8 (0.5-6.3) |
| ≥3 prior systemic therapy regimens, n (%) | 39 (54) | 5 (45) | 0 |
| Prior HSCT, n (%) | 21 (29) | 1 (9) | 0 |
MALT, mucosa-associated lymphatic tissue; MCL, mantle cell lymphoma; MZL, marginal zone lymphoma.
Includes American Indian, Alaska Native, Pacific Islander, and other.
Includes classic HL (n = 9) and nodular lymphocytic-predominant HL (n = 1).
Includes classic HL (n = 2).
Includes extranodal MZL of MALT type (n = 2), nodal MZL (n = 4), splenic MZL (n = 2), and unknown MZL subtype (n = 1).